Evidence map›Paper›PMID 40420360›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Experimental modeling of Alzheimer's disease: Translational lessons from cross-taxon analyses.

Konstantin B Yenkoyan, Maria M Kotova, Kirill V Apukhtin, David S Galstyan, Tamara G Amstislavskaya, Tatyana Strekalova, Murilo S de Abreu, Vergine A Chavushyan, Lee Wei Lim, Longen Yang and 2 more

Abstract readReview
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Experimental modeling of Alzheimer's disease: Translational lessons from cross-taxon analyses.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  13. Frontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Konstantin B YenkoyanNeuroscience Laboratory, COBRAIN Center, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.
Maria M KotovaNeuroscience Program, Sirius University of Science and Technology, Sochi, Russia.
Kirill V ApukhtinNeuroscience Program, Sirius University of Science and Technology, Sochi, Russia.
David S GalstyanInstitute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia.
Tamara G AmstislavskayaScientific Research Institute of Neurosciences and Medicine, Novosibirsk, Russia.
Tatyana StrekalovaResearch Institute of General Pathology and Pathophysiology, Moscow, Russia.
Murilo S de AbreuGraduate Program in Health Sciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil.
Vergine A ChavushyanNeuroscience Laboratory, COBRAIN Center, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.
Lee Wei LimDepartment of Biosciences and Bioinformatics, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China.
Longen YangLaboratory of Experimental Neuropsychobiology, Department of Biochemistry and Molecular Biology, Natural and Exact Sciences Center, Federal University of Santa Maria, Santa Maria, Brazil.
Denis D RosembergLaboratory of Experimental Neuropsychobiology, Department of Biochemistry and Molecular Biology, Natural and Exact Sciences Center, Federal University of Santa Maria, Santa Maria, Brazil.
Allan V KalueffSuzhou Municipal Key Laboratory of Neurobiology and Cell Signaling, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China.

Funding

Higher Education and Science Committee of the Republic of Armenia 21T-3A327;25YSMU-CON-I-3ASaint Petersburg State University ID 95443748Sirius University of Science and Technology NRB-RND-2116Xi'an Jiaotong-Liverpool University
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a severely debilitating neurodegenerative disease with a rapidly increasing global prevalence, poorly understood causes, and no efficient treatments. Experimental models are valuable for studying AD pathogenesis, including amyloid beta and tau accumulation, synaptic dysfunction, and neuroinflammation. While no model fully reproduces the disease, we take an evolutionary biology approach to discuss available models across taxa, from mammals (rodents, primates) to zebrafish, Drosophila melanogaster, and Caenorhabditis elegans. Evaluating their strengths and limitations provides insight into disease mechanisms and may refine research strategies for improved diagnostics and therapeutic screening. Traditional models have significantly contributed to AD research, yet their translational limitations highlight the need for physiologically relevant alternatives. Integrating humanized rodent models, zebrafish, organoids, and induced pluripotent stem cell-based systems-along with advances in bioengineering and genetic editing-may offer a more comprehensive framework to bridge the gap between preclinical research and clinical application. HIGHLIGHTS: Experimental models across rodents, primates, zebrafish, fruit flies, and worms provide key insights into Alzheimer's disease (AD). Cross-taxon comparisons assess strengths and weaknesses in AD models. Evolutionary biology approaches refine experimental strategies for AD research. Diverse animal models improve understanding of AD pathogenesis. Cross-species models enhance diagnostics and therapeutic strategy development.

Indexed as

Alzheimer DiseaseDisease Models, AnimalTranslational Research, BiomedicalAnimalsCaenorhabditis elegansDrosophila melanogasterHumansZebrafishAlzheimer's diseaseanimal modelscross‐taxon analysesevolutionary psychiatrytranslation medicine

Identifiers

PMID40420360
PMCPMC12106051

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.